← Leaderboards
Bruce C Marshall
University Of Utah
$261,106
Attributed
$261,106
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$261,106 · 6
By mechanism
M01$261,106 · 6
Top collaborators
No co-investigators on record.
Most similar at University Of Utah
Same institution · by research overlap
- Richard David Bland$7,249,780
- William M. Clemons$8,184,158
- Edward J Campbell$254,173
- Louis R Barrows$9,079,632
- Stephen L Guthery$6,633,340
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchCystic FibrosisHuman SubjectDrug Screening /EvaluationHuman Therapy EvaluationRespiratory Disorder ChemotherapyVolunteerAerosolsAminoglycoside AntibioticsBioassayDetergentsDrug Adverse EffectExperimental DesignsFamily GeneticsGenetic MarkersHuman Genetic Material TagIntestine ObstructionKanamycinLinkage MappingLiposomesParticlePharmacokineticsImmunopathologyPathologic Process
Grant awards (19)
AEROSOLIZED TYLOXAPOL IN THE AIRWAYS DISEASE OF CYSTIC FIBROSIS$0
M01 · FY2002 · RR
OPEN LABEL PILOT OF SAFETY, PHARMACOKINETICS, &EFFICACY OF MIKASOME$0
M01 · FY2002 · RR
CYSTIC FIBROSIS GENE MODIFIER STUDY$0
M01 · FY2002 · RR
OPEN LABEL PILOT OF SAFETY, PHARMACOKINETICS, &EFFICACY OF MIKASOME$248,088
M01 · FY2001 · RR
CYSTIC FIBROSIS GENE MODIFIER STUDY$1,637
M01 · FY2001 · RR
OPEN LABEL PILOT OF SAFETY, PHARMACOKINETICS, &EFFICACY OF MIKASOME$1,624
M01 · FY2001 · RR
STUDY OF NONTUBERCULOUS MYCOBACTERIA IN PATIENTS WITH CYSTIC FIBROSIS$1,624
M01 · FY2001 · RR
AEROSOLIZED TYLOXAPOL IN THE AIRWAYS DISEASE OF CYSTIC FIBROSIS$1,624
M01 · FY2001 · RR
AEROSOLIZED TYLOXAPOL IN THE AIRWAYS DISEASE OF CYSTIC FIBROSIS$0
M01 · FY2001 · RR
AEROSOLIZED TYLOXAPOL IN THE AIRWAYS DISEASE OF CYSTIC FIBROSIS$0
M01 · FY2001 · RR
CYSTIC FIBROSIS GENE MODIFIER STUDY$0
M01 · FY2001 · RR
CYSTIC FIBROSIS GENE MODIFIER STUDY$0
M01 · FY2001 · RR
OPEN LABEL PILOT OF SAFETY, PHARMACOKINETICS, &EFFICACY OF MIKASOME$0
M01 · FY2001 · RR
CYSTIC FIBROSIS GENE MODIFIER STUDY$1,637
M01 · FY2000 · RR
AEROSOLIZED TYLOXAPOL IN THE AIRWAYS DISEASE OF CYSTIC FIBROSIS$1,624
M01 · FY2000 · RR
OPEN LABEL PILOT OF SAFETY, PHARMACOKINETICS, &EFFICACY OF MIKASOME$1,624
M01 · FY2000 · RR
STUDY OF NONTUBERCULOUS MYCOBACTERIA IN PATIENTS WITH CYSTIC FIBROSIS$1,624
M01 · FY2000 · RR
CYSTIC FIBROSIS THERAPY--ALPHA-1 ANTITRYPSIN--ELASTASE$0
M01 · FY2000 · RR
LUNG SPECIFIC BIOEFFICACY--ORAL DMP 777 IN CYSTIC FIBROS$0
M01 · FY2000 · RR